ViaCyte

ViaCyte is a biotechnology startup from the United States, focused on developing revolutionary cell replacement therapies for long-term diabetes treatment, aiming to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are rooted in the directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, implanted in durable and retrievable cell delivery devices. The company has garnered attention through its collaborative partnerships with esteemed companies such as CRISPR Therapeutics and W.L. Gore & Associates, aiming to accelerate and expand its efforts. ViaCyte's pipeline includes the PEC-Direct product candidate, which is currently undergoing clinical evaluation and delivers PEC-01 cells in a non-immunoprotective device, catering to type 1 diabetes patients with specific conditions. Additionally, the PEC-Encap product candidate delivers pancreatic islet progenitor cells in an immunoprotective device, intended for all type 1 diabetes patients. Recently, ViaCyte attracted a Series D investment on 22 April 2021, with notable backers including Invus, Adage Capital Management, Asymmetry Ventures, and Artis Ventures (AV). The company showcases promising potential with its emphasis on regenerative medicine, aiming to transform the lives of patients with insulin-requiring diabetes, making it a compelling prospect for venture capital investment.